Pyrazolopyrimidinediones are a novel series of compounds that inhibit growth of Helicobacter pylori specifically. Using a variety of methods, advanced analogues were shown to suppress the growth of H. pylori through the inhibition of glutamate racemase, an essential enzyme in peptidoglycan biosynthesis. The high degree of selectivity of the series for H. pylori makes these compounds attractive candidates for novel H. pylori-selective therapy.Helicobacter pylori is a gram-negative pathogen whose colonization of the human gastric mucosa can cause gastritis that can lead to peptic ulceration (23). The organism is also implicated as a causative agent for certain types of gastric cancer (20,23,24,27), and therefore, eradication of the organism is advised for people with ulcer disease (5). Recommended therapies consist of a proton pump inhibitor in combination with broad-spectrum antibacterials, but emerging resistance and poor patient compliance compromise the effectiveness of these treatments (23). Thus, alternative therapies without these issues are needed for continued successful eradication of H. pylori in patients.The non-life-threatening nature and unique disease manifestation of H. pylori infections allow highly selective therapy directed only against the specific organism. The advantage of such a selective therapy would be to limit adverse effects caused by disturbances in the microbial gut flora, thereby improving patient compliance and reducing selection for resistance in other species.A target-based research program that integrated genetic, biochemical, biophysical, and structural characterization of targets was undertaken to identify selective targets for therapy directed against H. pylori (17). Glutamate racemase (MurI), an essential enzyme in peptidoglycan biosynthesis (11,12,25) (Fig. 1), was identified through these efforts as a potentially selective target for therapy directed against H. pylori. A highthroughput screen was carried out with the enzyme, and pyrazolopyrimidinediones were identified as a class of selective H. pylori MurI inhibitors that also showed whole-cell activity (17). This study describes the microbiological characterization of this class of inhibitors.(These studies were presented in part at the 2005 Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC [10a].)
MATERIALS AND METHODSBacterial strains and susceptibility testing. The bacterial strains, plasmids, and primers used in this study are listed in Table 1. Susceptibilities for H. pylori, Campylobacter coli, and Campylobacter jejuni were determined as described previously (16). MICs for anaerobic species were determined according to CLSI broth microdilution guidelines for Bacteroides fragilis (9). MICs for all other species were determined according to CLSI guidelines (10). Compounds were dissolved in dimethyl sulfoxide, and the final concentration of this solvent in all MIC assays was 2%, a concentration that was used as control.Frequency of spontaneous resistance development. Spontaneous frequenci...